This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Frova

Endo International plc

Drug Names(s): frovatriptan succinate, Allegro

Description: Frovatriptan is a 5-HT receptor agonist that binds with high affinity to 5-HT1B and 5-HT1D receptors. Frovatriptan has no significant effects on GABA mediated channel activity and has no significant affinity for benzodiazepine binding sites. Frovatriptan is believed to inhibit excessive dilation of extracerebral intracranial arteries in migraine.

Deal Structure: Vernalis originally licensed Frova from SmithKline Beecham in 1994. In 1998, SmithKline Beecham waived its option to commercialize the compound and worldwide marketing rights passed to Vernalis in return for a residual royalty payable to SmithKline Beecham on future worldwide sales of Frova. During 2000, in connection with SmithKline Beechams merger with Glaxo Wellcome plc, Vernalis made two major amendments to the 1994 agreement:

  • in July 2000, SmithKline Beecham assigned to Vernalis all of SmithKline Beechams patents covering Frova (with no substantive changes in the royalty arrangements); and
  • in December 2000, SmithKline Beecham waived all of its rights to royalties on sales of Frova in return for a series of five $5 million cash payments by Vernalis.
In March 2004, Vernalis reacquired the North American rights for Frova from Elan Pharma International Ltd (Elan) for a total of US$50 million payable over 21 months. On completion of the transaction, all rights and...See full deal structure in Biomedtracker

Partners: The Menarini Group Vernalis Group plc


Frova News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug